Nkarta, Inc. (NASDAQ:NKTX – Get Rating) insider James Trager sold 5,000 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $17.53, for a total transaction of $87,650.00. Following the sale, the insider now directly owns 62,172 shares of the company’s stock, valued at approximately $1,089,875.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Nkarta Price Performance
NKTX stock traded down $0.45 during midday trading on Wednesday, hitting $17.28. The stock had a trading volume of 244,854 shares, compared to its average volume of 1,459,319. The business has a 50-day moving average of $13.75 and a two-hundred day moving average of $12.43. The firm has a market cap of $570.41 million, a price-to-earnings ratio of -6.23 and a beta of 0.11. Nkarta, Inc. has a 52-week low of $7.55 and a 52-week high of $37.10.
Institutional Trading of Nkarta
Hedge funds have recently modified their holdings of the business. Quantbot Technologies LP increased its stake in shares of Nkarta by 39.1% in the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock worth $36,000 after acquiring an additional 900 shares in the last quarter. Wellington Management Group LLP grew its holdings in Nkarta by 5.9% in the first quarter. Wellington Management Group LLP now owns 27,879 shares of the company’s stock worth $317,000 after purchasing an additional 1,554 shares during the period. Rock Springs Capital Management LP grew its holdings in Nkarta by 0.5% in the first quarter. Rock Springs Capital Management LP now owns 509,948 shares of the company’s stock worth $5,803,000 after purchasing an additional 2,700 shares during the period. State Street Corp increased its stake in shares of Nkarta by 1.0% during the first quarter. State Street Corp now owns 276,318 shares of the company’s stock valued at $3,144,000 after purchasing an additional 2,806 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Nkarta by 2.0% during the fourth quarter. Northern Trust Corp now owns 148,984 shares of the company’s stock valued at $2,287,000 after purchasing an additional 2,883 shares during the last quarter. Institutional investors own 74.19% of the company’s stock.
Analyst Ratings Changes
NKTX has been the subject of several recent analyst reports. Cantor Fitzgerald lowered their price objective on shares of Nkarta from $60.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, August 12th. SVB Leerink assumed coverage on Nkarta in a research report on Monday, July 18th. They set an “outperform” rating and a $30.00 price target for the company. Needham & Company LLC started coverage on Nkarta in a research report on Thursday, July 28th. They issued a “buy” rating and a $26.00 price objective on the stock. HC Wainwright upped their target price on Nkarta from $25.00 to $36.00 and gave the company a “buy” rating in a report on Monday, April 25th. Finally, Raymond James lifted their price target on shares of Nkarta from $17.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, April 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $39.63.
Nkarta Company Profile
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.